More than 65% of women with ovarian cancer will experience recurrences. Second-line chemotherapeutic agents show promise in treating these recurrences, but there is no ideal method of early detection. By localizing residual or recurrent tumors not detected by standard radiographic modalities (eg, computed tomography), monoclonal antibody imaging may facilitate a more informed, cost-effective assessment of the relative risks and benefits of additional surgery, chemotherapy, or no further treatment in patients at risk.
|Original language||English (US)|
|Journal||Female Patient - OB/GYN Edition|
|State||Published - Dec 1 1995|
ASJC Scopus subject areas
- Obstetrics and Gynecology